{"name":"NTC srl","slug":"ntc-srl","ticker":"","exchange":"","domain":"ntcsrl.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Levofloxacin + dexamethasone followed by dexamethasone","genericName":"Levofloxacin + dexamethasone followed by dexamethasone","slug":"levofloxacin-dexamethasone-followed-by-dexamethasone","indication":"Bacterial infection with associated inflammation (specific indication not publicly detailed for this Phase 3 trial)","status":"phase_3"}]}],"pipeline":[{"name":"Levofloxacin + dexamethasone followed by dexamethasone","genericName":"Levofloxacin + dexamethasone followed by dexamethasone","slug":"levofloxacin-dexamethasone-followed-by-dexamethasone","phase":"phase_3","mechanism":"Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, while dexamethasone is a corticosteroid that suppresses inflammation and immune responses.","indications":["Bacterial infection with associated inflammation (specific indication not publicly detailed for this Phase 3 trial)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxObVhyTDFMWkNkZ0FDQl9GMjZ4dmI5UWFGOFY0d1lNMl9ib0hVS2J1ZEZwSWJXczJGU3hnT0l3YTNHbmI1cFh3UElsRURzcjM1WFFNbml5cDlwU0ZXYi1RS0haOW1ENDJrUUxVZVVURlhaTktycmJVdXJ5MWxibUxpMGM4X3JqLWJvNWxaclpURGo1a0xLSFFyQ3l5WHBRcmFtQWtoZ1NzU0Z2YWpCbjl2QmowRmYwZnlvaTBmV2pvaUhnU1ZpdnNGSFVrTFVtNmlabmx3ckpUb3ctX3JOLXc?oc=5","date":"2025-12-10","type":"pipeline","source":"prnewswire.com","summary":"NTC, BACKED BY WISE EQUITY, COMPLETES THE ACQUISITION OF PHARMATHEN'S OPHTHALMOLOGY BUSINESS - prnewswire.com","headline":"NTC, BACKED BY WISE EQUITY, COMPLETES THE ACQUISITION OF PHARMATHEN'S OPHTHALMOLOGY BUSINESS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxOVVBDaWs3bTMtMEtLc0p6WUlDZENFa0lRak03OFNnTUR1YURzVVI4VlBZMm1LMTlIYWF2d203VDVTTmpSNHdqOWxScklfZ2luYklTMndnWV9ibEdnY1hCTVZuZS1NWUN6dHFub1ZRNUpxcFFEem1UNHhzVXRURV9QdkdNT0NtOElOQjlOdWVXNmVXXzVfd0MzYkREUXRLQVgxUUhmX3VILXZtRDl0dG5wa2NJWm5zdFRFSUhBQzZ2RmtpSFdjaXFMajQwZ2dkYkU1eUtxRzByTVNGX1VUUkQzMDUwMjBSZ2taNjRjUQ?oc=5","date":"2024-12-06","type":"trial","source":"BioSpace","summary":"NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis - BioSpace","headline":"NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOMmQyenA0dUVIQTNkSVU0Rk1lMTNNaXBVcVlKLTRCdi1GemNLbnA0bzB3S0NydDFVOW01MWJnZE1LLUlQbEJqWmVKenpvTFQ3NVpKa0tvSzZJTEJ0LTdKT2E5WjFnSEVSX3lLOWZyTU1wWHAxTjRpZFpqaDBJNUw0Nw?oc=5","date":"2021-12-15","type":"deal","source":"Yahoo Finance","summary":"NTC and I-MED Pharma form strategic partnership to bring the leading HA-based dry eye ointment to the United States market - Yahoo Finance","headline":"NTC and I-MED Pharma form strategic partnership to bring the leading HA-based dry eye ointment to the United States mark","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxQM3VjZll3N2d0MGxEalloQjhzeUhyelcySVBuLVUtcnpsMUJacmFqb1EyNUExMTZkY1JmZnR6SXpHZFoxaXQyZnh5VV9pcHRRYWUxMEpaU1VTSTZqMks5SE5Xd09BNkg5Uko4Y3V3VThmeTE5Y3BramdobjA5ME45UmVFSkVzUVRHQUhXdHctZnVqQXBjblUzRDdSc0VobzBfRFBSd3hoTUNyYlVPOF9WXzJhMXA3WFBCMGY3Q01yZzZuSnp2UHZWUHNvcEdzS1RUSExKNHBoUTNlQWFoQWZYR0t5UzZzdzZMUTlET1dR?oc=5","date":"2018-05-31","type":"pipeline","source":"PR Newswire UK","summary":"NTC to Strengthen Its Ophthalmology Portfolio Through the Acquisition of Ocular Antibiotic Products - PR Newswire UK","headline":"NTC to Strengthen Its Ophthalmology Portfolio Through the Acquisition of Ocular Antibiotic Products","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}